Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.

ENCISION INC

CIK: 9307752 Annual ReportsLatest: 2025-07-10

10-K / July 10, 2025

Revenue:$6,555,315
Income:-$220,198

10-K / July 15, 2024

Revenue:$6,585,882
Income:-$691,783

10-K / July 10, 2025

Encision Inc. Company Summary

Business Overview

  • Industry: Medical Devices
  • Location: Boulder, Colorado
  • Core Technology: Active Electrode Monitoring (AEM®) Surgical Instruments
  • Purpose: Enhance patient safety in minimally invasive surgery (MIS) by preventing stray electrosurgical energy that can cause tissue burns, injuries, or fatalities.
  • Market Focus: Increase in MIS procedures (laparoscopy and robotic-assisted surgeries) and use of monopolar electrosurgery devices.
  • Key Benefits: Innovative, same size and functionality as conventional instruments, but incorporate patented shield and monitoring technology to continuously prevent unintended tissue damage.

Products

  • AEM Surgical Instruments: Full range of laparoscopy tools (scissors, graspers, dissectors, forceps, suction/irrigation devices) available in reusable and disposable formats.
  • AEM Monitors: Devices that connect with instruments to monitor electrical current flow and shut down energy if hazards are detected.
  • EndoShield® 2: Burn protection system, disposable and reprocessable, compatible with existing electrosurgical generators.
  • enTouch® Disposable Scissors: High-performance scissors with integrated AEM technology.
  • 2X enTouch® Scissors: Cost-effective, multi-use scissors with thermochromic indicators for usage tracking.
  • Accessories: Handles, tips, and other surgical components.

Market & Adoption

  • Market Size: Over 4.4 million laparoscopic procedures annually in the U.S.
  • Market Share Goals: Targeting a growing share in monopolar electrosurgical instrument market (~$500 million annual sales in the U.S.).
  • Adoption Path: Aiming to become a standard of care similar to pulse oximetry; endorsed by surgeons, nurses, insurers, legal, and medical communities.
  • Distribution: U.S. direct and independent sales reps, expanded hospital GPO agreements, and international distributors. CE marking obtained for European sales; expanding presence in Australia, New Zealand, Middle East, and Europe.
  • Customer Base: Hospitals, surgical centers, and healthcare providers implementing monopolar electrosurgery.

Employees and Financials

  • Employees: 22 full-time, 2 part-time (as of March 31, 2025).
  • Annual Revenue: Not explicitly provided.
  • Net Income: Not explicitly provided.
  • Research & Development Expenses: Approximately $593,152 in FY 2025, and $621,894 in FY 2024.
  • Funding & Capital: Primarily financed through stock offerings, options, loans; cash and equivalents of $257,433 as of March 31, 2025.

Regulation & Patents

  • Regulatory Status: Products are Class II medical devices (FDA) with a pending or existing approval process.
  • Patents: 21 active U.S. patents and additional patents internationally, protecting shielding and monitoring technologies.

Competitive Position

  • Differentiation: Only company offering a continuous solution that completely eliminates stray electrical energy risks.
  • Main Competitors: Larger medical device firms like Medtronic and Johnson & Johnson, plus alternative energy technologies such as bipolar electrosurgery, lasers, and ultrasonic devices.
  • Industry Challenges: Market acceptance, regulatory approvals, competition from well-established firms, and technological advancements.

Note: Specific revenue, profit, or customer numbers are not provided in the document.
The summary is based solely on the detailed information given in the provided excerpt.